Further development is required to speed commercialisation

    • Pre-clinical studies for influenza to refine the dose levels and vaccination schedules
    • Phase 1/2 clinical trials for influenza
    • Parallel development for TB
    • Exploration of other uses for the technology

To enable this, we are seeking an investment of £20 million. We anticipate results within 18 months.